Skip to main content
Premium Trial:

Request an Annual Quote

DNA Direct to Provide Personalized Reports for Iverson's Warfarin Sensitivity Test

NEW YORK (GenomeWeb News) - DNA Direct and Iverson Genetic Diagnostics said today that they are collaborating to provide personalized reports for customers of Iverson's warfarin-sensitivity assay.
Under the terms of the agreement, DNA Direct will provide a customized, web-based report for Iverson customers that will explain their test results in a “patient-friendly, interactive format,” the companies said.
The reports will be “personalized to the patient's test results,” the companies said, and will explain the implications for both general drug response and warfarin dosing, as well as how genes affect drug response, what factors impact dosing of the blood thinner, and what next steps may be most appropriate.
Patients will be able to download a copy of their lab report, as well as a clinical summary letter that they can share with their physicians.
Iverson’s Warfarin Dosing Panel XP identifies seven different variations of the CYP2C9 gene and nine different variations of the VKORC1 gene that play a role in determining response to warfarin.

The Scan

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.

Tibetan Study Finds Adaptive Variant Influencing Skin Pigmentation

With a combination of phenotyping and genetic data, researchers document at PNAS a Tibetan-enriched enhancer variant influencing melanin synthesis and ultraviolet light response.

Domestication Linked to Nervous System Genes in Inbred Mouse Strains

Researchers highlighted more than 300 positively selected genes in domesticated mice, including genes linked to nervous system function or behavior in Genome Biology.

ALS Genetic Testing May Be Informative Across Age Ranges, Study Finds

Researchers in the journal Brain identified clinically actionable variants in a significant subset of older ALS patients, prompting them to point to the potential benefits of broader test use.